Provision Nashville staff poses with its ASTRO APEx Accreditation certificate

Press Ganey, ASTRO recognize Provision for Culture and Quality of Care

By

Provision is excited to announce that we have recently received distinguished recognition from two separate, well-reputed organizations in the healthcare industry. Provision CARES Proton Therapy Nashville was awarded the Press Ganey 2021 Guardian of Excellence Award®, garnering national attention for our Culture of Care for the second year in a row. In addition, Provision Nashville also achieved accreditation from the American Society for Radiation Oncology’s Accreditation Program for Excellence® (APEx), further demonstrating our commitment to excellence in safety and quality in patient-centered care.

CONTINUE READING

Provision takes healthcare safety and security very seriously

‘Healthcare Safety & Security Week’ highlights Provision’s commitment to patients

By

Each year during the second week of October, healthcare facilities around the country recognize “Healthcare Security & Safety Week.” This is a chance to send our appreciation to all the professionals out there who work hard to make sure the facilities we rely on for our healthcare needs are safe and secure. This includes everything from the physical safety of patients and staff to virtual security of medical records and personal health information.

Provision is 100% committed to the health and safety of our patients and staff, as well as the security of their private information. Not only have we implemented robust safety policies and training, but we’ve even designated several staff members to serve on our dedicated Safety Committee.

CONTINUE READING

Members of Blue Origin's Radiation Effects Team pose while testing space travel equpiment at Provision CARES Proton Therapy Knoxville

How protons created an unlikely connection between cancer treatment and space travel

By

What do you envision when you look at the sky and think of outer space?

We recently had the pleasure of chatting with Merek Chertkow of Blue Origin, an aerospace company whose mission is to benefit the Earth by one day sending millions of people to live and work in space. (Side note: Just days after we spoke to him, Blue Origin made headlines by successfully completing New Shepard’s first human flight!)

CONTINUE READING

Year in review 2020 at Provision CARES Proton Therapy

Year in Review: 2020 at Provision CARES Proton Therapy

By

Writing a “Year in Review” blog feels a little different in 2020. We typically think back fondly on the year that was; remembering the moments that made it so great. For most of us though, “great” might not be the first word that comes to mind when we think of 2020.

A global pandemic gripped the world and brought with it fear, anxiety, uncertainty, and unfortunately, tragedy. While we can’t ignore the reality of 2020, we can still choose to look beyond the surface of it. We can choose to find the positive, the admirable, and the inspirational.

Here are some of the highlights from 2020 at Provision CARES Proton Therapy. As you close out this tumultuous year, perhaps a reminder of the good that still came out of it will help lead you into 2021 with a sense of hope and optimism.

…CONTINUE READING

Study finds PSA test for prostate cancer has long-term benefits

PSA test for prostate cancer offers long-term benefits, study finds

By

September is Prostate Cancer Awareness Month and it’s common to hear public service announcements reminding men to get a prostate-specific antigen (PSA) test. Afterall, prostate cancer is the second leading cause of cancer death among American men and early detection is the best prevention.

However, recent recommendations from the U.S. Preventive Services Task Force (USPSTF) cast doubt on whether the potential risks associated with PSA screening are worth the reward. Now though, new research suggests those risks may be exaggerated.

The long-term benefits of the PSA test for prostate cancer may outweigh any potential harm according to a recent paper published in the New England Journal of Medicine (NEJM). While current guidelines advise patients and physicians to determine the value of routine PSA screening on a case-by-case basis, researchers suggest that perceptions of PSA tests as ineffective are based on overstated harms and point to evidence showing that screenings can reduce death rates and prevent metastatic disease.

…CONTINUE READING

Delaying cancer screening tests during COVID puts patients at risk

Delayed cancer screenings in COVID era put patients at risk

By

When the COVID-19 pandemic began, life as we knew it came to an abrupt halt. That included routine healthcare visits, as many providers postponed appointments and cancer screening tests that were deemed “non-essential.”

In the United States alone, an estimated 22 million cancer screening tests were disrupted by COVID-19 from April to June 2020. As a result, about 80,000 patients could be at risk for delayed or missed diagnoses.

The IQVIA Institute for Human Data Science recently published these estimates as part of its report on shifts in healthcare demand, delivery and care during the COVID-19 era. In this article, we’ll look at how diagnostic procedures for some of the most common cancers are impacted. We’ll also share some tips to help you move forward with your cancer-related care in a timely and safe manner.

…CONTINUE READING